Table 4 Data for subjects that completed all visits (n = 12)
SC | BL | PUR118 | PUR118 | PUR118 | ||
|---|---|---|---|---|---|---|
2.8 mg dose | 5.5 mg dose | 11.0 mg dose | ||||
Sputum: | ||||||
Viability | % | 84.5 (12.4) | 85.5 (12.1) | 81.1 (13.0) | 82.2 (13.3) | 85.0 (11.6) |
TCC | 106/mL | 1.6 (0.9) | 2.7 (1.9) | 3.6 (3.2) | 2.2 (1.4) | 3.4 (4.7) |
AM | % | 62.0 (23.9) | 27.2 (16.4) | 23.7 (22.4) | 16.6 (18.6) | 16.2 (21.2) |
CD14 + MO | % | 2.3 (1.8) | 5.9 (2.2) | 7.9 (4.5) | 5.3 (3.6) | 6.1 (3.6) |
NG | % | 29.5 (23.0) | 63.7 (23.4) | 58.1 (21.4) | 71.0 (23.4) | 69.3 (22.0) |
LY | % | 1.5 (1.6) | 1.1 (1.4) | 0.6 (0.4) | 0.7 (0.6) | 0.8 (0.6) |
EO | % | 0.0 (0.5) | 0.3 (0.5) | 0.5 (0.6) | 0.5 (0.7) | 0.3 (0.3) |
FE | % | 2.8 (5.8) | 1.3 (3.0) | 9.8 (11.8) | 2.7 (7.7) | 3.4 (5.5) |
AM | 106/mL | 0.9 (0.5) | 0.6 (0.7) | 0.7 (0.6) | 0.4 (0.4) | 0.5 (0.6) |
CD14 + MO | 106/mL | 0.0 (0.1) | 0.2 (0.1) | 0.2 (0.2) | 0.2 (0.1) | 0.2 (0.2) |
NG | 106/mL | 0.2 (0.6) | 1.7 (1.9) | 2.1 (2.5) | 1.5 (1.3) | 2.3 (3.2) |
EO | 106/mL | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) |
LY | 106/mL | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) |
FE | 106/mL | 0.1 (0.1) | 0.0 (0.1) | 0.2 (0.2) | 0.1 (0.2) | 0.1 (0.2) |
Blood: | ||||||
WBC | 106/mL | 4.5 (1.4) | 8.6 (1.9) | 8.2 (2.6) | 8.3 (2.3) | 8.4 (2.8) |
NG | % | 56.5 (9.5) | 67.8 (9.2) | 63.3 (11.2) | 64.1 (4.0) | 64.3 (6.1) |
MO | % | 10.3 (2.3) | 7.8 (2.1) | 8.3 (1.8) | 8.3 (2.0) | 7.8 (2.4) |
LY | % | 28.1 (11.8) | 22.0 (8.6) | 24.5 (10.8) | 24.4 (7.4) | 23.9 (5.1) |
EO | % | 2.1 (1.8) | 1.5 (1.2) | 2.2 (1.3) | 1.8 (0.9) | 1.7 (0.4) |
BA | % | 0.7 (0.3) | 0.3 (0.1) | 0.3 (0.1) | 0.4 (0.3) | 0.4 (0.2) |